Beta(2)-glycoprotein 1-dependent anticardiolipin antibod- ies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke. 2001;32:1701 1706. 820. JanardhanV, Wolf PA, Kase CS, Massaro JM, D Agostino RB, Franzblau C, Wilson PW. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke. 2004;35:736 741. 821. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphos- pholipid syndrome. Blood. 2003;102:2717 2723. 822. Heinzlef O, Abuaf N, Cohen A, Amarenco P; French Study of Aortic Plaques in Stroke Group. Recurrent stroke and vascular events in elderly patients with anticardiolipin antibodies: a prospective study. J Neurol. 2001;248:373 379. 823. PengoV, RuffattiA, Legnani C, Testa S, Fierro T, Marongiu F, De Micheli V, Gresele P, Tonello M, Ghirarduzzi A, Bison E, Denas G, Banzato A, Padayattil Jose S, Iliceto S. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118:4714 4718. 824. Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S, Scarpato S, Montecucco C, Rossi S, Caramaschi P, Biasi D, Doria A, Rampudda M, Monica N, Fischetti F, Picillo U, Brucato A, Salvan E, Vittorio P, Meroni P, Tincani A; Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis. 2011;70:1083 1086. 825. Petri M. Management of thrombosis in antiphospholipid antibody syn- drome. Rheum Dis Clin North Am. 2001;27:633 642, viii. 826. Chan M, Becker RC, Shah SH, Levine SR. Coagulopathy and stroke. In: Goldstein LB, ed. A Primer on Stroke Prevention and Treatment: an Overview Based on AHA/ASA Guidelines. Oxford, UK: Wiley- Blackwell; 2009:152 169. 827. 